PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Mount Sinai and Cancer Research Institute team up to improve patient outcomes in immunotherapy

New partnership aims to deepen understanding of immune response in cancer treatment

2025-06-17
(Press-News.org)

New York, NY [June 17, 2025]—In a new collaboration that could transform how cancer is treated, OCCAM Immune—a Mount Sinai initiative focused on understanding the immune system’s role in disease—is partnering with the Cancer Research Institute (CRI) to unlock the secrets of how the immune system responds to advanced therapies.

Under the agreement, OCCAM Immune and CRI have established a long-term plan to support ongoing immune monitoring across CRI’s clinical trials. The collaboration provides a flexible framework for launching new projects efficiently and will focus on tracking how patients’ immune systems respond to treatment, with the goal of identifying which patients are most likely to benefit from certain immunotherapies and why.

The collaboration was sparked by Thomas Marron, MD, PhD, Director of the Early Phase Trial Unit at The Tisch Cancer Institute at Mount Sinai and Chief Medical Officer of OCCAM Immune. Recognizing a shared vision between the two organizations, Dr. Marron brought Mount Sinai and CRI together to accelerate progress in immunotherapy, a treatment that helps the body’s own immune system fight cancer.

“We’re thrilled to team up with the Cancer Research Institute on this important work. CRI brings decades of experience in cancer immunotherapy and access to rich clinical trial samples from around the world,” says Dr. Marron. “At OCCAM Immune, we’re bringing powerful tools to analyze the immune system and the expertise to turn complex data into insights that matter to doctors, scientists, and, ultimately, patients. By working together, we aim to better understand how different therapies interact with the immune system and use that knowledge to make cancer care more personalized and effective.”

Immunotherapy has transformed cancer treatment, but it doesn’t work for everyone. OCCAM Immune is helping uncover why by mapping how the immune system responds to therapy—insights that can improve care not just for cancer, but for autoimmune and inflammatory diseases as well. By combining clinical expertise with advanced lab tools, OCCAM Immune supports researchers and companies worldwide in developing more precise, effective therapies.

OCCAM Immune operates in collaboration with Mount Sinai’s robust medical and research ecosystem, led by pioneers including Miriam Merad, MD, PhD, whose work has shaped our understanding of how the immune system controls cancer. Dr. Merad is Dean for Translational Research and Therapeutic Innovation, Director of the Marc and Jennifer Lipschultz Precision Immunology Institute (PrIISM), and Chair of Immunology and Immunotherapy at the Icahn School of Medicine at Mount Sinai. Through PrIISM, OCCAM Immune offers partners access to rare clinical samples, cutting-edge analysis, and a proven track record of discovery.

“We are proud to partner with OCCAM Immune and Mount Sinai on this important effort to advance our understanding of how the immune system responds to cancer therapies,” says Alicia Zhou, PhD, CRI’s Chief Executive Officer. “OCCAM Immune’s expertise in immune profiling and data interpretation, paired with CRI’s network of immunotherapy trials, creates a powerful synergy. Together, we’re not only accelerating the pace of discovery but also moving closer to a future where every patient receives the treatment most likely to be effective for them.”

The collaborative work is set to begin with a clinical trial in women with ovarian cancer, where researchers will closely study immune cells and tumors from patients treated with novel drug combinations. The focus will be on platinum-resistant high-grade serous ovarian cancer, an aggressive type of ovarian cancer that often returns after treatment. OCCAM Immune scientists will analyze 160 blood samples and tumor biopsies using cutting-edge technologies like RNA/DNA sequencing and immune cell mapping. They aim to understand how the body responds to these treatments and identify markers that could help match future patients with the most effective therapies.

“This collaboration with the Cancer Research Institute marks an important step forward—not just for OCCAM Immune, but for the field of immunotherapy as a whole,” says Dr. Merad. “It reflects growing recognition of our ability to generate and interpret high-quality immune data, which is essential as personalized medicine and AI-driven drug development continue to advance. We’re delighted to partner with CRI and other leaders across academia, biotech, and pharma to accelerate discoveries that help unlock the full potential of the immune system and improve outcomes for patients.”

OCCAM Immune

As an academic research organization within Mount Sinai, OCCAM Immune combines identifying unique biomarkers with deep expertise in profiling to monitor immune responses before and during therapy. OCCAM Immune bridges academic research and clinical practice by providing scientific insight, innovative tools, and tailored services to academic, non-profit and industry partners. Supporting research in immuno-oncology, allergy, autoimmunity, and infectious diseases, OCCAM Immune delivers actionable insights to optimize immunotherapy and improve clinical trial outcomes.

The Cancer Research Institute

The Cancer Research Institute (CRI) is a nonprofit founded in 1953, dedicated to advancing immunotherapy to treat, control, and cure all cancers. The CRI funds scientists worldwide to explore new avenues of discovery and develop lifesaving immunotherapies. Through its Cancer Immunotherapy Clinical Trial Finder, CRI connects patients with cutting-edge clinical trials, providing them with potential new treatment options and contributing to the cancer research that will make immunotherapy a standard treatment for all cancers. By supporting innovative research and promoting clinical trials, CRI aims to create a world immune to cancer, offering hope and improved outcomes for patients globally. 

The Department of Immunology and Immunotherapy

Established in June 2023, the Department of Immunology and Immunotherapy at the Icahn School of Medicine at Mount Sinai advances the institution’s rich legacy of immunobiological research. With a focus on the fundamental mechanisms of immune cell function and development, the Department aims to drive innovation that deepens our understanding of immunity in health and disease.

The Tisch Cancer Institute

The Tisch Cancer Institute, a leading National Cancer Institute-Designated Cancer Center, drives innovation in cancer prevention, research, and treatment through a multidisciplinary, patient-centered approach. Established in 2008 and home to more than 150 leading scientists and physicians, the Institute builds on Mount Sinai’s legacy to deliver clinical breakthroughs—such as advances in immunotherapy—that improve the lives of patients and their families.

About the Icahn School of Medicine at Mount Sinai 

The Icahn School of Medicine at Mount Sinai is internationally renowned for its outstanding research, educational, and clinical care programs. It is the sole academic partner for the seven member hospitals* of the Mount Sinai Health System, one of the largest academic health systems in the United States, providing care to New York City’s large and diverse patient population.  

The Icahn School of Medicine at Mount Sinai offers highly competitive MD, PhD, MD-PhD, and master’s degree programs, with enrollment of more than 1,200 students. It has the largest graduate medical education program in the country, with more than 2,600 clinical residents and fellows training throughout the Health System. Its Graduate School of Biomedical Sciences offers 13 degree-granting programs, conducts innovative basic and translational research, and trains more than 560 postdoctoral research fellows. 

Ranked 11th nationwide in National Institutes of Health (NIH) funding, the Icahn School of Medicine at Mount Sinai is among the 99th percentile in research dollars per investigator according to the Association of American Medical Colleges.  More than 4,500 scientists, educators, and clinicians work within and across dozens of academic departments and multidisciplinary institutes with an emphasis on translational research and therapeutics. Through Mount Sinai Innovation Partners (MSIP), the Health System facilitates the real-world application and commercialization of medical breakthroughs made at Mount Sinai.

------------------------------------------------------- 

* Mount Sinai Health System member hospitals: The Mount Sinai Hospital; Mount Sinai Brooklyn; Mount Sinai Morningside; Mount Sinai Queens; Mount Sinai South Nassau; Mount Sinai West; and New York Eye and Ear Infirmary of Mount Sinai.  

 

 

 

 

 

 

END



ELSE PRESS RELEASES FROM THIS DATE:

Suicide risk elevated among young adults with disabilities

2025-06-17
Suicide remains one of the most pressing public health crises affecting young adults today, with devastating consequences. According to the United States Centers for Disease Control and Prevention, suicide is currently the third leading cause of death among individuals aged 18 to 25, with a 51% increase in suicide deaths between 2000 and 2021. While this trend is deeply concerning for the general population, it is even more alarming for young adults living with intellectual and developmental disabilities (IDD) – a group long overlooked in suicide prevention efforts. Research ...

Safeguarding Mendelian randomization: editorial urges rethink in methodological rigor

2025-06-17
In recent years, Mendelian randomisation (MR) has revolutionised observational epidemiology by offering a tool to infer causal relationships using genetic variants as instrumental variables (IVs). However, its popularity has come at a cost. The editorial by Chen, Guillot, and Schneider in eGastroenterology (2025) titled "Attention to the misuse of Mendelian randomisation in medical research" delivers a timely critique of the field's current trajectory. As MR studies surge, so too do concerns about their quality and interpretive validity. The authors call for stricter methodological scrutiny and offer practical recommendations ...

Using AI to find persuasive public health messages and automate real-time campaigns

2025-06-17
AI can help public health agencies in the quest to end HIV. The United States is pursuing an initiative to end the HIV epidemic by 2030. To achieve this goal, public health agencies and organizations must remind the public about how best to avoid transmitting and acquiring the virus. Public health campaigns are costly, their effectiveness is seldom systematically assessed, and no systematic methods have been developed to build health campaigns in real-time. Dolores Albarracin and colleagues collected public health messages about HIV prevention and testing from US federal agencies, non-profit organizations, ...

Gene therapy for glaucoma

2025-06-17
Gene editing could be used to treat millions of glaucoma patients. Glaucoma is a leading cause of blindness, characterized by high pressure inside the eye. Patients often rely on daily eye drops to lower intraocular pressure, but the drops may cause significant complications including bradycardia, metabolic acidosis, and kidney stones. In addition, many patients fail to keep up with the eye drops. Yang Sun and colleagues used the CRISPR gene editing technique to knock down two genes associated with the production ...

Teaching robots to build without blueprints

2025-06-17
Bees, ants and termites don’t need blueprints. They may have queens, but none of these species breed architects or construction managers. Each insect worker, or drone, simply responds to cues like warmth or the presence or absence of building material. Unlike human manufacturing, the grand design emerges simply from the collective action of the drones — no central planning required. Now, researchers at Penn Engineering have developed mathematical rules that allow virtual swarms of tiny robots to do the same. In computer simulations, the robots built honeycomb-like structures without ever following — or even being able to comprehend — ...

Negative perception of scientists working on AI

2025-06-17
A public survey indicates that Americans have negative opinions of scientists who work on AI. Dror Walter and colleagues collected opinions about scientists from thousands of US adults via the Annenberg Science and Public Health survey and compared the perceived credibility, prudence, unbiasedness, self-correction, and benefit of scientists working on AI with those of scientists in general and climate scientists in particular. Previous work has established that high scores on these dimensions predict support for science ...

How disrupted daily rhythms can affect adolescent brain development

2025-06-17
A new McGill University-led study suggests that disrupting the body’s internal clock during adolescence can alter how the brain responds to an in-utero risk factor linked to certain brain disorders. Previous research has shown that a mother’s infection during pregnancy, such as the flu, can increase a child’s risk of developing conditions like schizophrenia and autism spectrum disorders later in life. Irregular sleep patterns – often a sign of circadian rhythm disruption – are also associated with these conditions. To investigate how these factors interact, researchers exposed mice to either a ...

New use for old drug: study finds potential of heart drug for treating growth disorders

2025-06-17
Bone growth occurs through the proliferation of specialized cells of the cartilage tissue, known as chondrocytes, on either end of a bone. This process requires the synthesis of extracellular matrix (ECM) in the bone growth plates. A peptide hormone, known as C-type natriuretic peptide (CNP), plays a pivotal role by binding to its specific receptors present on the chondrocytes and triggering a signaling cascade in these cells. The CNP-bound receptor activates a molecule, cyclic guanosine monophosphate (cGMP), which in turn activates ...

Head-to-head study shows bariatric surgery superior to GLP-1 drugs for weight loss

2025-06-17
WASHINGTON, DC – June 17, 2025 – Sleeve gastrectomy and gastric bypass were associated with about five-times more weight loss than weekly injections of GLP-1 receptor agonists semaglutide or tirzepatide,* at the end of two years, according to a new head-to-head real-world study presented today at the American Society for Metabolic and Bariatric Surgery (ASMBS) 2025 Annual Scientific Meeting. Researchers from NYU Langone Health and NYC Health + Hospitals discovered patients who had one of the bariatric procedures lost an average 58 pounds after two years compared to 12 pounds ...

Psychiatric disorders less likely after weight-loss surgery than treatment with GLP-1s

2025-06-17
WASHINGTON, DC – June 17, 2025 – People who have metabolic and bariatric surgery are significantly less likely to develop psychiatric disorders compared to those who take weekly injections of GLP-1 anti-obesity medications, according to a new study* presented today at the American Society for Metabolic and Bariatric Surgery (ASMBS) 2025 Annual Scientific Meeting. Over a five-year period, the risk of developing cognitive deficits was 54% lower and 18% and 17% lower for anxiety disorders and substance use ...

LAST 30 PRESS RELEASES:

New CZI AI model could help scientists pinpoint signs of cancer cells

Sugar-coated ‘sticky’ stem cells could unlock surgery-free liver treatments

Children’s social media activity highlights emotional stress of living with long-term health issues

New tool maps hidden roles and risks in ecosystems

New breakthrough method to protect quantum spins from noise

Chemicals from turmeric and rhubarb could help fight antibiotic-resistant bacteria lurking in wastewater

Instant cancer diagnosis with light and AI!

New electroenzymatic strategy enables non-natural oxidation reactions

Tunable laser light

Scientists uncover magnetic-field control of ultrafast spin dynamics in 2D ferromagnets

New AI-powered model accurately predicts lung motion with minimal radiation

AI language models show promise in predicting liver cancer treatment outcomes

Tracking insect and bug health in a heartbeat from a digital camera

'Talking fish' not heard by conservation policies, SFU study warns

Thirty years of research shows increased resistance in fungi

Junk food ‘avoids advertising regulation’ with top level UK sports sponsorship

Banking on AI while committed to net zero is ‘magical thinking’, claims report on energy costs of big tech

Ancient river systems reveal Mars was wetter than we thought

Online toolkit to help parents of autistic children improve dental health

The psychological and neurological parallels between sports fandom and religious devotion

Agricultural liming in the US is a large CO2 sink, say researchers

Seaside more likely to make us nostalgic than green places, study finds

Psilocybin delays aging, extends lifespan, Emory study suggests

Buck Institute awarded DARPA contract to pioneer next-gen AI modeling platform

Orange is the new aphrodisiac—for guppies

Murals boost Cincinnati’s vitality, community development

Ad blockers may be showing users more problematic ads, NYU Tandon study finds

Verbal response time reveals hidden sleepiness in older adults

University of Maryland School of Medicine launches groundbreaking study on THC/CBD therapy for dementia-related agitation at end of life

Targeting stem-property and vasculogenic mimicry for sensitizing paclitaxel therapy of triple-negative breast cancer by biomimetic codelivery

[Press-News.org] Mount Sinai and Cancer Research Institute team up to improve patient outcomes in immunotherapy
New partnership aims to deepen understanding of immune response in cancer treatment